Literature DB >> 12119743

Angiogenesis modulation in cancer research: novel clinical approaches.

Massimo Cristofanilli1, Chusilp Charnsangavej, Gabriel N Hortobagyi.   

Abstract

Angiogenesis--the formation of new blood vessels--is essential for tumour progression and metastasis. Consequently, the modulation of tumour angiogenesis using novel agents has become a highly active area of investigation in cancer research, from the bench to the clinic. However, the great therapeutic potential of these agents has yet to be realized, which could, in part, be because the traditional strategies that are used in clinical trials for anticancer therapies are not appropriate for assessing the efficacy of agents that modulate angiogenesis. Here, we discuss methods for monitoring the biological activity of angiogenic modulators, and innovative approaches to trial design that might facilitate the integration of these agents into anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119743     DOI: 10.1038/nrd819

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  30 in total

1.  Novel human-derived extracellular matrix induces in vitro and in vivo vascularization and inhibits fibrosis.

Authors:  Marc C Moore; Vittoria Pandolfi; Peter S McFetridge
Journal:  Biomaterials       Date:  2015-02-11       Impact factor: 12.479

2.  Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development.

Authors:  Yuchen Liu; Luming Zhao; Dameng Li; Yuan Yin; Chen-Yu Zhang; Jing Li; Yujing Zhang
Journal:  Protein Cell       Date:  2013-11-07       Impact factor: 14.870

3.  Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.

Authors:  Arup Bhattacharya; Mukund Seshadri; Steven D Oven; Károly Tóth; Mary M Vaughan; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

Review 4.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

5.  Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma.

Authors:  Lei-Bo Xu; Chao Liu; Guo-Quan Gao; Xian-Huan Yu; Rui Zhang; Jie Wang
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

6.  Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model.

Authors:  Marianne O Stefanini; Florence T H Wu; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Cancer Res       Date:  2010-11-30       Impact factor: 12.701

7.  Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors.

Authors:  Trevor P Wade; Piotr Kozlowski
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

8.  Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.

Authors:  Xueming Wu; Eun-Kee Jeong; Lyska Emerson; John Hoffman; Dennis L Parker; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

9.  YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.

Authors:  Youzhi Xu; Hongjun Lin; Nana Meng; Wenjie Lu; Guobo Li; Yuanyuan Han; Xiaoyun Dai; Yong Xia; Xiangrong Song; Shengyong Yang; Yuquan Wei; Luoting Yu; Yinglan Zhao
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.

Authors:  Nikki Cheng; Dana Brantley; Wei Bin Fang; Hua Liu; William Fanslow; Douglas Pat Cerretti; Katrin N Bussell; Alastair Reith; Dowdy Jackson; Jin Chen
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.